Disseminated visceral fusariosis treated with amphotericin B-phospholipid complex.
Fusariosis, a rare infectious disease of the immunocompromised host, is relatively resistant to amphotericin B (AmB) or other antifungal agents. We describe a 5-year follow-up of a 40 year old woman with T-type acute lymphoblastic leukemia who following chemotherapy developed prolonged high fever, chills, night sweats, and severe weakness. Liver function tests were impaired and abdominal computerized tomography (CT) showed multiple lesions in the liver and abnormal structure of the spleen. A laparotomy revealed multiple granulomas containing Fusarium sp. in the liver, and the spleen was heavily infiltrated by the same fungus. The patient failed to respond to the conventional AmB dosage form (Fungizone) even after a total dose of 3.0 g was given, and developed significant renal impairment. AmB was complexed (in a mole ratio of 1:16) with a mixture of the phospholipids dimyristoyl phosphatidylcholine and dimyristoyl phosphatidylglycerol (mixed in 7:3 mole ratio). The resulting drug complex, AmB-PLC, was then administered (1-4 mg/kg/day, total dose 4.2 g) and subsequently the patient was cured of all symptoms of fusariosis. There were only mild side effects and no nephrotoxicity was evident. On the contrary, marked improvement of the renal function tests occurred during AmB-PLC treatment. Eight months later, she developed a spinal lesion with dense consistency in L5 and S1, and after receiving another course of AmB-PLC (3.1 g) she recovered completely. In a 2 year follow-up period the patient had no further relapse of the fungal disease. Subsequent chemotherapy given for relapse of the leukemia was followed by a new fungal infection, which was treated with AmB-cholesteryl sulfate complex (Amphocil).(ABSTRACT TRUNCATED AT 250 WORDS)
Engelhard
D
D
Department of Clinical Microbiology, Hadassah University Hospital, Jerusalem, Israel.
Eldor
A
A
Polacheck
I
I
Hardan
I
I
Ben-Yehuda
D
D
Amselem
S
S
Salkin
I F
IF
Lopez-Berestein
G
G
Sacks
T
T
Rachmilewitz
E A
EA
D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004134:Dimyristoylphosphatidylcholine / Q000008:administration & dosage*; D004337:Drug Carriers; D005260:Female; D005500:Follow-Up Studies; D005670:Fusarium / Q000302:isolation & purification*; D006099:Granuloma / Q000150:complications / Q000188:drug therapy / Q000382:microbiology; D006505:Hepatitis / Q000150:complications / Q000188:drug therapy / Q000382:microbiology*; D006801:Humans; D016867:Immunocompromised Host; D007674:Kidney Diseases / Q000139:chemically induced / Q000517:prevention & control; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000150:complications / Q000188:drug therapy; D009181:Mycoses / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications; D010715:Phosphatidylglycerols / Q000008:administration & dosage*; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D012008:Recurrence; D013158:Splenic Diseases / Q000150:complications / Q000188:drug therapy / Q000382:microbiology*; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D004337:Drug Carriers; D010715:Phosphatidylglycerols; D014750:Vincristine; D000666:Amphotericin B; C002773:dimyristoylphosphatidylglycerol; D001215:Asparaginase; D004134:Dimyristoylphosphatidylcholine; D011241:Prednisone; D003630:Daunorubicin